A carregar...
Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors
BACKGROUND: Activating mutations in JAK1 and JAK2 have been described in patients with various hematologic malignancies including acute lymphoblastic leukemia and myeloproliferative neoplasms, leading to clinical trials with JAK inhibitors. While there has been a tremendous effort towards the develo...
Na minha lista:
| Main Authors: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Ferrata Storti Foundation
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3105646/ https://ncbi.nlm.nih.gov/pubmed/21393331 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2010.036350 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|